Page 112 - CIBEREHD2016-ENG

LEAD rESEArCHEr
Pérez Gisbert, Javier
Servicio Madrileño de Salud
Hospital Universitario La Princesa
C/ Diego de León 62 28006 Madrid
(+34) 91 309 39 11 [email protected] group Website
GROUP MEMBERS
Staff members: Calvo Albinelli, Jorge | Durán Vegue, Almudena | Marín Gómez, Alicia C. | Mcnicholl, Adrian Ger | Montalbán Arques, Ana Ma | Pérez Nyssen, Olga | Ribot Rodríguez, Rosa | Rodríguez Perera, Eva Ma Associated members: Abad Santos, Francisco | Bernardo, David | Chaparro Sánchez, María | González Guijarro, Luis Alberto | Santander Vaquero, Cecilio | Torrado Durán, Santiago
Main lines of research
The Gastrointestinal Inflammatory Disease Group, from La Princesa University Hospital in Madrid (and its network of affiliated researcher), focuses on the understanding and management of Inflammatory Bowel Disease (IBD) and Helicobacter pylori infection.
MILESTONES
• AEG-REDCap Platform
- Direction and coordination of the Online Platform for Collaborative Research AEG-REDCap (>50 projects and 1,000 researchers).
- Management of the AEG-REDCao strategic line and agreement at CIBEREHD.
• H. pylori infection
- International coordination of the European Registry on H. pylori management (250 hospitals, 27 Countries).
- In situ and in vivo detection and treatment with multifunctional nanomaterials.
- Effect of eradication treatment on intestinal microbiota.
- Validation of new diagnostic methods.
- Prevalence/transmission/resistance, and sociosanitary factors of infection.
• Inflammatory Bowel Disease
Clinical research. Coordination and participation in over 20 clinical trials and studies in different phases, with the participation of numerous CIBER centers; the most outstanding ones are:
- “Prospective and multicentre study on the epidemiology and “omic” characteristics of newly diagnosed IBD in Spain” (FIS16/01296). / “Withdrawal of anti-TNF treatment in patients with IBD: Multicenter, prospective and randomized clinical trial” (FIS15/00560). / “Predicting short- and long-term response to treatment with anti-TNF drugs in patients with Crohn’s disease. Predicrohn Study (FIS12/02557). / “Long-
112
PROGRAMMES
P2